EFFECT OF ACHIEVING DAPSA-LDA ON THE PROGRESSION OF BONE EROSION AND ENTHESIOPHYNES IN PATIENTS WITH PSORIATIC ARTHRITIS: A LONGITUDINAL HR-PQCT STUDY

WU Doroze1, James F. Griffith2, Steven H.M. Lam1, Priscilla C. Wong3, Lin Shi3, Edmund K. Li1, Isaac T. Cheng1, K. Li Tena1, Vivian W. Hung1, Ling Qin4, Lai-Shan Tam1, 1The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China; 2The Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Imaging and Interventional Radiology, Hong Kong, China; 3The Prince of Wales Hospital, The Chinese University of Hong Kong, Research Centre for Medical Image Computing, Department of Imaging and Interventional Radiology, Hong Kong, China; 4The Chinese University of Hong Kong, Bone Quality and Health Centre, Department of Orthopaedics and Traumatology, Hong Kong, Hong Kong (SAR)

Background: Psoriatic arthritis (PsA) is characterized by structural bone damage with bone erosions and enthesiophytes. Whether achieving low disease activity (LDA) according to Disease Activity in Psoriatic Arthritis (DAPSA-LDA) limits progression of structural bone damage, as assessed by high resolution-peripheral quantitative computed tomography (HR-pQCT), is uncertain.

Objectives: To investigate the progression of structural bone abnormalities at the metacarpal head in patients with PsA over a 5-year period.

Methods: HR-pQCT examination was performed in 60 PsA patients at baseline and after 5 years. Baseline-indexed image registration and slice matching were performed to acquire precisely matched baseline and follow-up volumes of interest (VOI) at the 2nd and 3rd metacarpal heads (MCH2 & 3). A semi-automated method was used to calculate bone erosion and enthesiophyte volume [1]. Erosion and enthesiophyte progression was defined as change exceeding the smallest detectable change (SDC).

The primary objective of this study was to investigate the degree of bone erosion and enthesiophyte progression in PsA patients receiving routine care. Secondary objectives were to compare changes in bone erosion and enthesiophyte volume between patients who 1) received TNFi therapy or did not receive TNFi therapy; 2) achieved or did not achieve sustained DAPSA-LDA at both baseline and 5-year.

Results: A total of 108 bone erosions and 99 enthesiophytes were detected at baseline. Three new bone erosions and no new enthesiophytes were evident at 5 years. Mean (±SD) individual bone erosion (4.23±3.15 mm3) and enthesiophyte (3.39±2.30 mm3) volume at baseline increased significantly (0.58±1.50 mm3, p<0.001 for bone erosion; 0.47±0.76 mm3, p<0.001 for enthesiophyte volume) over a 5-year period despite disease modifying anti-rheumatic drug being used in 88.3% of patients (Figure 1). The total bone erosion (7.83±7.41 mm3) and enthesiophyte volume (5.59±5.46 mm3) per patient also increased by 1.07±2.16 mm3 (p<0.001) and 0.78±1.11 mm3 (p<0.001) respectively. 14 patients received TNFi throughout the 5-year period. Comparable changes in bone erosion and enthesiophyte volume were found between the TNFi and the non-TNFi groups. After 5 years, 26 (43%) patients achieved sDAPSA-LDA. Less erosion progression (12/51 [23.5%] vs 25/60 [41.7%, P=0.047] was observed those who did rather than did not achieve sDAPSA-LDA. Similarly, enthesiophyte volume change (0.28±0.67 vs 0.61±0.80 mm3; P=0.049) and total enthesiophyte volume change (0.42±0.69 vs 1.05±1.29 mm3; P=0.019) were lower in those who did rather than did not achieve sDAPSA-LDA.

Conclusion: Once DAPSA-LDA is achieved, it should be maintained for a long period so as to minimize progression of structural bone damage in patients with PsA.

REFERENCE


Disclosure of Interests: None declared


SECTORAL CHANGES IN PSORIATIC ARTHRITIS PATIENTS STARTING FIRST COURSE OF BIOLOGIC THERAPIES – INFLAMMATORY HALLMARKS OF LESSER PREMIONENCE: A NORDIC POPULATION-BASED COHORT STUDY

1Beckbea L. Hansen, Tanja Schjødt Jørgensen1,2, Lene Dreyer1,2, Bjørn Gudbrandsen3, Johan Askling4, Merete L. Heltand3, Bente Glintborg4, Daniela Di Giuseppe3, Lennart T.H. Jacobsson5, Tore K. Kvien6, Dan Nordstrøm7, Kalle Aaltonen8, Sela Areastad Provan9, Erik Kristianslund4, Johan K. Wallmark4, Thorvardur Jon Love10, Lars Erik Kristensen11, 1 Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Imaging and Interventional Radiology, Hong Kong, Hong Kong; 2The Prince of Wales Hospital, The Chinese University of Hong Kong, Research Centre for Medical Image Computing, Department of Imaging and Interventional Radiology, Hong Kong, Hong Kong; 3The Chinese University of Hong Kong, Bone Quality and Health Centre, Department of Orthopaedics and Traumatology, Hong Kong, Hong Kong (SAR)

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disorder associated with skin and joint manifestations, several extra-articular symptoms, various comorbidities, and disability[1,2]. The emergence of tumour necrosis factor inhibitor (TNFi) therapy has dramatically changed the course of disease. Additional TNFi therapies (certolizumab pegol and golimumab) have been marketed, and recently ustekinumab has become available for PsA.

Objectives: To assess the use of biological agents (bDMARDs) in PsA from 2006–2017, using data from the Nordic Rheumatology registers.

Methods: Based on data from the registers DANBIO, ICEBIO, NOR-DMARD, ROB-FIN, and SRQ, PsA patients initiating bDMARDs or biosimilars, as a first or subsequent biological therapy were identified. Adalimumab, etanercept and infliximab were grouped as 1st generation therapies; certolizumab pegol, golimumab were grouped as 2nd generation therapies and biosimilar treatments were grouped. Treatments with ustekinumab were also identified. Pearson correlation tests were calculated and p<0.05 were considered significant. Rs^2=1 showed a strong correlation between the baseline characteristics.

Results: A total of 18,089 treatment initiations were identified (DANBIO 4,361, ICEBIO 449, NOR-DMARD 1,948, ROB-FIN 1,069, SRQ 10,262). 53.68% of the patients were female. Overall, 6,198 patients initiated 1st generation therapies, 1,447 2nd generation therapies, 1,533 biosimilars and 52 ustekinumab, as their first course of bDMARDs. Initiations of second or subsequent bDMARDs were 4,560, 1,630, 2,176 and 376 patients, respectively. The total of first course bDMARD initiators increased significantly from 2006-2017 (p<0.001), similar to patients switching therapy (p<0.001). Ustekinumab was primarily used as a second or subsequent bDMARD. The figure shows the secular trends of baseline characteristics collected from the Nordic countries with the subcategories of CRP, disease duration, HAQ score, VAS patient pain, swollen joint count and tender joint count from 2006-2017. All five countries showed trends of decreasing CRP, SJC and TJC values over time. Other parameters only showed slight or no correlation.


Disclosure of Interests: None declared

REFERENCE


Disclosure of Interests: None declared